Prescribers and pharmacies who were unable to complete online certification for the new Clozapine Risk Evaluation and Mitigation Strategy Program due to technical issues should try again because the problem was resolved as of Friday, the Food and Drug Administration announced yesterday. FDA last month announced changes to the requirements for monitoring, prescribing, dispensing and receiving the schizophrenia medicine to address continuing safety concerns about a serious blood condition called severe neutropenia. Prescribers or pharmacists who continue to encounter technical issues with the Clozapine REMS Program should contact the program at 844-267-8678, FDA said. “If prescribers and pharmacists continue to experience any issues, they should use clinical judgment and consider the best interests of the patient,” the agency said. “Continue prescribing and dispensing clozapine to patients with an absolute neutrophil count within the acceptable ranges while the issues are being resolved.”

Related News Articles

Headline
More than 880,000 physicians were certified by the American Board of Medical Specialties in 2017, about 20,000 more than in 2016, according to the board’…
Headline
The Centers for Medicare & Medicaid Services has identified the first clinicians eligible to participate in 2018 advanced alternative payment models, based…
Headline
The National Collaborative for Improving the Clinical Learning Environment this week released guidance to help health care system leaders work with clinical…
Headline
In a letter this week, the AHA again urged the Centers for Medicare & Medicaid Services to take specific actions to address and prevent the serious…
Headline
AHA has activated The Care Fund to provide support to hospital employees in Puerto Rico who experienced significant property loss or damage from any natural…
Headline
The Centers for Disease Control and Prevention this week launched Rx Awareness, a communications campaign to educate the public about the risks associated with…